Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goals of this clinical study are to learn more about the study drug lenacapavir (LEN), by comparing the consistent and continuous use of LEN and emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®) (F/TDF), then by observing the safety of LEN and F/TDF, evaluating the acceptability of LEN injections and oral F/TDF, and observe how LEN moves throughout the body in people who would benefit from pre-exposure prophylaxis (PrEP).
The primary objective of this study is to compare LEN and F/TDF consistent and continuous use among people who would benefit from PrEP.
Phase:
PHASE2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination lenacapavir Tenofovir